Cited by 838Immunotherapy and Immune ResponsesImmune Response and InflammationCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

Open access

Chiba, Shigeki, Baghdadi, Muhammad, Akiba, Hisaya, Yoshiyama, Hironori, Kinoshita, Ichiro, Dosaka-Akita, Hirotoshi, Fujioka, Yoichiro, Ohba, Yusuke, Gorman, Jacob V, Colgan, John D, Hirashima, Mitsuomi, Uede, Toshimitsu, Takaoka, Akinori, Yagita, Hideo, Jinushi, Masahisa·2012·Nature Immunology

DOI 10.1038/ni.2376PMC PMC3622453

Open this paper in CoChat — free account

Abstract

The mechanisms by which tumor microenvironments modulate nucleic acid-mediated innate immunity remain unknown. Here we identify the receptor TIM-3 as key in circumventing the stimulatory effects of nucleic acids in tumor immunity. Tumor-associated dendritic cells (DCs) in mouse tumors and patients with cancer had high expression of TIM-3. DC-derived TIM-3 suppressed innate immune responses through the recognition of nucleic acids by Toll-like receptors and cytosolic sensors via a galectin-9-independent mechanism. In contrast, TIM-3 interacted with the alarmin HMGB1 to interfere with the recruitment of nucleic acids into DC endosomes and attenuated the therapeutic efficacy of DNA vaccination and chemotherapy by diminishing the immunogenicity of nucleic acids released from dying tumor cells. Our findings define a mechanism whereby tumor microenvironments suppress antitumor immunity mediated by nucleic acids.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/ni.2376

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Taking dendritic cells into medicine
Steinman, R. M., & Banchereau, J. (2007) · Nature · doi:10.1038/nature06175 · Cited by 2,162
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,747
HMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437

Flagged first, then by citations

Show all 50 references

Sorted by citations

Items 501–600 of 838

Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE)
Haratani, K., Nakamura, A., Mamesaya, N., Mitsuoka, S., Yoneshima, Y., Saito, R., Tanizaki, J., Fujisaka, Y., Hata, A., Tsuruno, K., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.06.012 · Cited by 17
Tim-3 pathway dysregulation and targeting in sepsis-induced immunosuppression
Luo, J., Zhang, C., Chen, D., Chang, T., Chen, S., Lin, Z., Yi, C., & Tang, Z. (2024) · European journal of medical research · doi:10.1186/s40001-024-02203-w · Cited by 17
Orthogonally Engineered Bacteria Capture Metabolically Labeled Tumor Antigens to Improve the Systemic Immune Response in Irradiated Tumors
Xia, W., Feng, Z., Wang, Y., Lei, R., Zhou, Y., Zhuo, Y., Xie, R., Dong, H., Zhao, X., Guan, X., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c13320 · Cited by 18
Tim-3 signaling blockade with α-lactose induces compensatory TIGIT expression in Plasmodium berghei ANKA-infected mice
Zhang, Y., Jiang, N., Zhang, T., Chen, R., Feng, Y., Sang, X., Yang, N., & Chen, Q. (2019) · Parasites & Vectors · doi:10.1186/s13071-019-3788-x · Cited by 17
Modulation of the Gut Microbiota Alters the Tumour-Suppressive Efficacy of Tim-3 Pathway Blockade in a Bacterial Species- and Host Factor-Dependent Manner
Lee, B., Lee, J., Woo, M.-Y., Lee, M. J., Shin, H., Kim, K. H., & Park, S. (2020) · Microorganisms · doi:10.3390/microorganisms8091395 · Cited by 17
A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy
Kuang, Z., Li, L., Zhang, P., Chen, B., Wu, M., Ni, H., Yi, S., Zou, J., & Liu, J. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa022 · Cited by 17
Molecular heterogeneity of CD30+ diffuse large B-cell lymphoma with prognostic significance and therapeutic implication
Huo, Y., Xu, P., Fu, D., Yi, H., Huang, Y., Wang, L., Wang, N., Ji, M.-M., Liu, Q.-X., Shi, Q., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00644-2 · Cited by 17
Expression and anatomical distribution of TIM-containing molecules in Langerhans cell sarcoma
Li, J., Cao, D., Guo, G., Wu, Y., & Chen, Y. (2012) · Journal of Molecular Histology · doi:10.1007/s10735-012-9475-2 · Cited by 17
Acute stimulation generates Tim‐3‐expressing T helper type 1 CD 4 T cells that persist in vivo and show enhanced effector function
Gorman, J. V., & Colgan, J. D. (2018) · Immunology · doi:10.1111/imm.12890 · Cited by 17
Self-citation
Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
Sasikumar, P. G., & Ramachandra, M. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100073 · Cited by 17
Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy
Li, Y., Kang, Z., & Du, Y. (2026) · Medicine Bulletin · doi:10.1002/mdb2.70018 · Cited by 18
A novel and effective approach to generate germline-like monoclonal antibodies by integration of phage and mammalian cell display platforms
Jin, Y.-J., Yu, D., Tian, X., Li, H., Zhou, X.-C., Kong, Y., Zhang, W., Zhang, L., Cheng, L., Yang, Z., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00707-3 · Cited by 16
Tim-3 downregulation by Toxoplasma gondii infection contributes to decidual dendritic cell dysfunction
Xie, H., Li, Z., Zheng, G., Yang, C., Liu, X., Xu, X., Ren, Y., Wang, C., & Hu, X. (2022) · Parasites & Vectors · doi:10.1186/s13071-022-05506-1 · Cited by 16
TIM-3 increases the abundance of type-2 dendritic cells during Leishmania donovani infection by enhancing IL-10 production via STAT3
Mishra, M., Yadav, M., Kumar, S., Kumar, R., & Sen, P. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05848-3 · Cited by 16
Non-Coding RNA in Tumor Cells and Tumor-Associated Myeloid Cells—Function and Therapeutic Potential
Binder, A. K., Bremm, F., Dörrie, J., & Schaft, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137275 · Cited by 16
Tim-3 promotes tube formation and decreases tight junction formation in vascular endothelial cells
Cong, Y., Wang, X., Wang, S., Qiao, G., Li, Y., Cao, J., Jiang, W. G., & Cui, Y. (2020) · Bioscience Reports · doi:10.1042/bsr20202130 · Cited by 16
Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-κB Signal Pathways
Liu, Z., Xiang, C., Han, M., Meng, N., Luo, J., & Fu, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.584530 · Cited by 16
T cell immunoglobulin and mucin domain‐containing molecule 3 on CD 14+ monocytes serves as a novel biological marker for diabetes duration in type 2 diabetes mellitus
Yan, W., Sun, P., Wei, D., Wang, S., Yang, J., Li, Y., & Zhang, C. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12523 · Cited by 16
Targeting novel inhibitory receptors in cancer immunotherapy
Ding, Q., Chauvin, J.-M., & Zarour, H. M. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101436 · Cited by 16
Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
Terenziani, R., Zoppi, S., Fumarola, C., Alfieri, R. R., & Bonelli, M. A. (2021) · Cancers · doi:10.3390/cancers13112793 · Cited by 16
A Comprehensive Review of Long Non-Coding RNAs in the Cancer–Immunity Cycle: Mechanisms and Therapeutic Implications
Perez-Medina, M., Benito-Lopez, J. J., Aguilar‐Cázares, D., & López-González, J. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104821 · Cited by 15
Redox-sensitive high mobility group box 1 (HMGB1) is a multifunctional regulator of cellular senescence, inflammation, and immunosuppression: Impact on the aging process
Salminen, A. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102926 · Cited by 15
Dynamic localization and the associated translocation mechanism of HMGBs in response to GCRV challenge in CIK cells
Rao, Y., Su, J., Yang, C., Yan, N., Chen, X., & Feng, X. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.55 · Cited by 15
Role of Tim-3 in regulating tumorigenesis, inflammation, and antitumor immunity therapy
Cao, Y., Li, Q., Liu, H., He, X., Huang, F., & Wang, Y. (2021) · Cancer Biomarkers · doi:10.3233/cbm-210114 · Cited by 15
The HIV-1 accessory protein Nef increases surface expression of the checkpoint receptor Tim-3 in infected CD4+ T cells
Jacob, R. A., Edgar, C. R., Prévost, J., Trothen, S. M., Lurie, A., Mumby, M. J., Galbraith, A., Kirchhoff, F., Haeryfar, S. M. M., Finzi, A., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101042 · Cited by 15
Tim-3 inhibits low-density lipoprotein-induced atherogenic responses in human umbilical vein endothelial cells
Qiu, M., Wang, S., Tang, Y., Pan, C., Wang, S., Wang, S.-Q., Quan, Z., & Ou, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17720 · Cited by 15
Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model
Zhang, Y., Liu, Z., Hao, X., Li, A., Zhang, J., Carey, C. D., Falo, L. D., & You, Z. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2087-7 · Cited by 15
Immunoregulation effects of TIM-3 on tumors
Sheng, C. C., & Han, F. (2018) · Neoplasma · doi:10.4149/neo_2018_180610n385 · Cited by 15
The association of HMGB1 expression with clinicopathological significance and prognosis in Asian patients with colorectal carcinoma: a meta-analysis and literature review
Yu, J., Zhang, X., Li, M., Zhu, H., Sun, X., & Kong, L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105512 · Cited by 14
An Emerging Role of TIM3 Expression on T Cells in Chronic Kidney Inflammation
Lu, C., Chen, H., Wang, C., Yang, F., Li, J., Liu, H., & Chen, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.798683 · Cited by 14
Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
Long, Y., Yu, X., Chen, R., Tong, Y., & Gong, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910704 · Cited by 14
Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer
Chang, H., Marquez, J., Chen, B. K., Kim, D. M., Cheng, M. L., Liu, E. V., Yang, H. L., Zhang, L., Sinha, M., Cheung, A., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0184 · Cited by 14
The role of TIM-3 in sepsis: a promising target for immunotherapy?
Wang, C., Liu, J., Wu, Q., Wang, Z., Hu, B., & Bo, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328667 · Cited by 14
Monoclonal antibody against human Tim‐3 enhances antiviral immune response
Li, G., Hou, C., Dou, S., Zhang, J., Zhang, Y., Liu, Y., Wang, Z., He, X., Wang, R., Chen, G., et al. (2018) · Scandinavian Journal of Immunology · doi:10.1111/sji.12738 · Cited by 14
Tim-3 is a potential regulator that inhibits monocyte inflammation in response to intermittent hypoxia in children with obstructive sleep apnea syndrome
Wang, W., Xu, Z., Zhang, J., Wang, S., Ge, W., Li, X., Mou, W., Wang, X., Chai, W., Zhao, J., et al. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108641 · Cited by 14
Differences in Immune Checkpoints Expression (TIM-3 and PD-1) on T Cells in Women with Recurrent Miscarriages—Preliminary Studies
Zych, M., Roszczyk, A., Kniotek, M., Dabrowski, F. A., & Zagożdżon, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184182 · Cited by 14
The role of immune regulatory molecules in rheumatoid arthritis: Implication for etiopathogenesis and prospective for treatment
Hemmatzadeh, M., Parvin, E. A., Mohammadi, H., Azizi, G., Shomali, N., & Jadidi‐Niaragh, F. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30855 · Cited by 15
Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells
Jinushi, M., Yagita∥, H., Yoshiyama, H., & Tahara, H. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.06.001 · Cited by 15
Self-citation
Role of dendritic cells in the regulation of antitumor immunity
Wathelet, N., & Moser, M. (2013) · OncoImmunology · doi:10.4161/onci.23973 · Cited by 14
Alpha-lactose reverses liver injury via blockade of Tim-3-mediated CD8 apoptosis in sepsis
Wei, Z., Li, P., Yao, Y., Deng, H., Yi, S., Zhang, C., Wu, H., Xie, X., Xia, M., He, R., et al. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.04.010 · Cited by 14
Restoration of stemness-high tumor cell-mediated suppression of murine dendritic cell activity and inhibition of tumor growth by low molecular weight oyster polysaccharide
Zhong, M., Zhong, C. F., Hu, P., Cui, W., Wang, G., Gao, H., Liu, C., Liu, Z., Li, Z.-H., Li, C., et al. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.10.003 · Cited by 14
Inhibitory receptors of plasmacytoid dendritic cells as possible targets for checkpoint blockade in cancer
Tiberio, L., Laffranchi, M., Zucchi, G., Salvi, V., Schioppa, T., Sozzani, S., Prete, A. D., & Bosisio, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1360291 · Cited by 13
The Role of TIM-3 in Glioblastoma Progression
Ahmady, F., Sharma, A., Achuthan, A. A., Kannourakis, G., & Luwor, R. B. (2025) · Cells · doi:10.3390/cells14050346 · Cited by 14
T Cell Immunoglobulin Mucin Domain (TIM)-3 Promoter Activity in a Human Mast Cell Line
Kim, J. S., Shin, D.-C., Woo, M.-Y., Kwon, M., Kim, K. H., & Park, S. (2012) · Immune Network · doi:10.4110/in.2012.12.5.207 · Cited by 13
Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations
Madondo, M., Tuyaerts, S., Turnbull, B. B., Vanderstraeten, A., Kohrt, H. E. K., Narasimhan, B., Amant, F. C., Quinn, M. A., & Plebanski, M. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-179 · Cited by 13
Programming the immune checkpoint to treat hematologic malignancies
Vick, E. J., & Mahadevan, D. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1175433 · Cited by 13
Les « immune checkpoints », comment ça marche
Granier, C., Soumelis, V., Mandavit, M., Gibault, L., Belazzoug, R., Guillebon, É. D., Badoual, C., Tartour, É., & Roussel, H. (2017) · Annales de Pathologie · doi:10.1016/j.annpat.2016.12.007 · Cited by 13
Recent Advances in Costimulatory Blockade to Induce Immune Tolerance in Liver Transplantation
Ding, M., He, Y., Zhang, S., & Guo, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.537079 · Cited by 13
Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer
Muaibati, M., Abasi, A., Zhang, T., Dai, Y., Li, R., Huang, F., Li, K., Tong, Q., Huang, X., & Zhuang, L. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.3 · Cited by 13
The Role of Inflammatory Cytokines in Creating T Cell Exhaustion in Cancer
Sabzevary‐Ghahfarokhi, M., Shirzad, H., Rafieian‐Kopaei, M., Ghatrehsamani, M., & Shohan, M. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2449 · Cited by 13
Bioinspired nucleic acid structures for immune modulation
Louttit, C., Park, K. S., & Moon, J. J. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119287 · Cited by 13
Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics
Sun, H., Huang, D., Zhang, H., Dong, M., Wang, S., Sun, M., Liu, J., Wang, Y., Qu, X., Li, X., et al. (2025) · MedComm – Oncology · doi:10.1002/mog2.70030 · Cited by 12
TIM-3 Expression on Dendritic Cells in Colorectal Cancer
Sakuma, M., Katagata, M., Okayama, H., Nakajima, S., Saito, K., Sato, T., Fukai, S., Tsumuraya, H., Onozawa, H., Sakamoto, W., et al. (2024) · Cancers · doi:10.3390/cancers16101888 · Cited by 12
Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus
Nakamura, H., Konnai, S., Okagawa, T., Maekawa, N., Sajiki, Y., Watari, K., KAMITANI, K., Saito, M., Kato, Y., Suzuki, Y., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01430-22 · Cited by 12
Combining in Situ Vaccination and Immunogenic Apoptosis to Treat Cancer
Kalami, A., Shahgolzari, M., Khosroushahi, A. Y., & Fiering, S. (2023) · Immunotherapy · doi:10.2217/imt-2022-0137 · Cited by 12
Parapharyngeal liposarcoma: a case report
Li, H., Zhou, X., Ran, Q., & Wang, L. (2013) · Diagnostic Pathology · doi:10.1186/1746-1596-8-42 · Cited by 12
Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?
Hossain, S. M., Lynch‐Sutherland, C. F., Chatterjee, A., Macaulay, E. C., & Eccles, M. R. (2021) · Epigenomes · doi:10.3390/epigenomes5030016 · Cited by 11
Immune evasion by cancer stem cells ensures tumor initiation and failure of immunotherapy
Chakraborty, S., Mukherjee, S., Basak, U., Pati, S., Dutta, A., Dutta, S., Dhar, S., Sarkar, T., Guin, A., Sa, G., et al. (2023) · Exploration of Immunology · doi:10.37349/ei.2023.00108 · Cited by 11
Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice
Sorkhabi, A. D., Komijani, E., Sarkesh, A., Shadbad, P. G., Aghebati‐Maleki, A., & Maleki, L. A. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01289-9 · Cited by 11
Involvement of Tim-3 in Maternal-fetal Tolerance: A Review of Current Understanding
Meng, X., Luo, Y., Cui, L., & Wang, S. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.106115 · Cited by 11
Structure and Functions of T-cell Immunoglobulin-domain and Mucin- domain Protein 3 in Cancer
Lu, X. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210806120904 · Cited by 11
How Tim proteins differentially exploit membrane features to attain robust target sensitivity
Kerr, D. H. S., Gong, Z., Suwatthee, T., Luoma, A., Roy, S., Scarpaci, R., Hwang, H. L., Henderson, J. M., Cao, K. D., Bu, W., et al. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.09.016 · Cited by 11
The Features of Checkpoint Receptor—Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition
Kuzevanova, A. Y., Апанович, Н. В., Mansorunov, D., Коротаева, А. А., & Karpukhin, A. V. (2022) · Biomedicines · doi:10.3390/biomedicines10092081 · Cited by 12
siRNA-Mediated B7H7 Knockdown in Gastric Cancer Lysate-Loaded Dendritic Cells Amplifies Expansion and Cytokine Secretion of Autologous T Cells
Masoumi, J., Ghorbaninezhad, F., Saeedi, H., Safaei, S., Khaze, V., Jolfayi, A. G., Naseri, B., Baghbanzadeh, A., Baghbani, E., Mokhtarzadeh, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11123212 · Cited by 11
Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses
Jinushi, M. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9501-9 · Cited by 11
Self-citation
Interaction of TIM4 and TIM3 induces T helper 1 cell apoptosis
Ge, R.-T., Zeng, L., Mo, L., Xu, L., Zhang, H., Yu, H., Zhang, M., Liu, Z., Liu, Z., & Yang, P. (2015) · Immunologic Research · doi:10.1007/s12026-015-8702-9 · Cited by 11
Negative Regulation of RIG-I by Tim-3 Promotes H1N1 Infection
Shi, Q., Li, G., Dou, S., Tang, L., Hou, C., Wang, Z., Gao, Y., Gao, Z., Hao, Y., Mo, R., et al. (2022) · Immunological Investigations · doi:10.1080/08820139.2022.2113407 · Cited by 11
Galectins expressed differently in genetically susceptible C57BL/6 and resistant BALB/c mice during acute ocularToxoplasma gondiiinfection
CHEN, S.-J., ZHANG, Y.-X., Huang, S., & Lu, F. (2017) · Parasitology · doi:10.1017/s0031182017000270 · Cited by 11
Increased circulating levels of High Mobility Group Box 1 (HMGB1) in acute-phase Chikungunya virus infection: Potential disease biomarker
Rocha, D. C. P., de Souza, T. M. A., Nunes, P. C. G., Mohana‐Borges, R., Paes, M. V., Guimarães, G. M. C., Sánchez‐Arcila, J. C., Paiva, I. A., de Azeredo, E. L., Damasco, P. V., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.105054 · Cited by 10
A Dual Enhancing Strategy of Novel Nanovaccine Based on TIM3 Silencing Nanoadjuvants and Desialylated Cancer Cell Membrane Antigens for Personalized Vaccination Immunotherapy of Cancer
Li, K., Li, X., Wu, J. J., Wu, H., Wu, M., Zhou, Y., Ya, L., Zou, Y., Jiang, X., & Xu, H. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202404956 · Cited by 10
Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models
Ausejo‐Mauleon, I., Martínez-Vélez, N., Lacalle, A., de la Nava, D., Cebollero, J., Villanueva, H., Casares, N., Marco-Sanz, J., Laspidea, V., Becher, O. J., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.175257 · Cited by 10
TIM-3 on myeloid cells promotes pulmonary inflammation through increased production of galectin-3
Kim, K. S., Lee, C., Kim, H.-S., Gu, S. J., Yoon, H. J., Won, S. B., Lee, H., Lee, Y. S., Kim, S. S., Kane, L., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06762-w · Cited by 10
Reduced T and NK Cell Activity in Glioblastoma Patients Correlates with TIM-3 and BAT3 Dysregulation
Ahmady, F., Curpen, P., Perriman, L., Teixeira, A. F., Wu, S., Zhu, H., Poddar, A., Jayachandran, A., Kannourakis, G., & Luwor, R. B. (2024) · Cells · doi:10.3390/cells13211777 · Cited by 10
Triggering immunogenic death of cancer cells by nanoparticles overcomes immunotherapy resistance
Mei, T., Ye, T., Huang, D., Xie, Y., Xue, Y., Zhou, D., Wang, W., & Chen, J. (2024) · Cellular Oncology · doi:10.1007/s13402-024-01009-6 · Cited by 10
The immune checkpoint LAG-3 is expressed by melanoma cells and correlates with clinical progression of the melanoma
Wiecken, M., Machiraju, D., Chakraborty, S., Mayr, E.-M., Lenoir, B., Eurich, R., Richter, J., Pfarr, N., Halama, N., & Hassel, J. C. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2430066 · Cited by 10
Negative Immune Checkpoint Inhibitors
Drewniak‐Świtalska, M., Fortuna, P., & Krzystek‐Korpacka, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060713 · Cited by 10
Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies
Alibrahim, M. N., Carbone, A., Alsaleh, N., & Gloghini, A. (2025) · Cancers · doi:10.3390/cancers17142292 · Cited by 13
Inhibition of TFEB promotes tumor-educated dendritic cells activation to enhance antitumor immune responses
Ding, J., Xie, Y., Sun, X. Y., Shao, F., Pan, J., Chen, J., Zhu, Z., & Qi, C. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.04.011 · Cited by 10
Characterization of a lipid droplet and endoplasmic reticulum stress related gene risk signature to evaluate the clinical and biological value in hepatocellular carcinoma
Guo, Z., & Liang, J. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01759-y · Cited by 10
Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature
Yadav, R., Hakobyan, N., & Wang, J. C. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512502 · Cited by 10
Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity
Yang, L., Li, S., Chen, L., & Zhang, Y. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0241 · Cited by 10
DNA sensing of dendritic cells in cancer immunotherapy
Qian, W. P., Ye, J., & Xia, S. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1391046 · Cited by 10
Cellular and molecular immunology of lung cancer: therapeutic implications
Nguyen, A. H., Berim, I. G., & Agrawal, D. K. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.975692 · Cited by 10
Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer
Waki, K., Kawano, K., Tsuda, N., Ushijima, K., Itoh, K., & Yamada, A. (2017) · Journal of Immunology Research · doi:10.1155/2017/1423683 · Cited by 10
HMGB1 suppresses colon carcinoma cell apoptosis triggered by co‑culture with dendritic cells via an ER stress‑associated autophagy pathway
Zheng, Y., & Zhu, G. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.8202 · Cited by 10
Fecal bacteria from ulcerative colitis patients downregulate Tim-3-mediated inhibitory effects on monocytes in vitro
Wang, S., Liu, Y., Yuan, X., Yao, L., Yang, S., & Ma, R. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.12.043 · Cited by 10
Comprehensive Phenotyping of Dendritic Cells in Cancer Patients by Flow Cytometry
Carenza, C., Franzese, S., Calcaterra, F., Mavilio, D., & Bella, S. D. (2020) · Cytometry Part A · doi:10.1002/cyto.a.24245 · Cited by 10
RepSox Slows Decay of CD34+ Acute Myeloid Leukemia Cells and Decreases T Cell Immunoglobulin Mucin-3 Expression
Jajosky, A. N., Coad, J. E., Vos, J. A., Martin, K. H., Senft, J. R., Wenger, S. L., & Gibson, L. F. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0193 · Cited by 10
The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment
Vorontsova, A., Kan, T., Raviv, Z., & Shaked, Y. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123912 · Cited by 10
Deciphering the roles of the HMGB family in cancer: Insights from subcellular localization dynamics
Jiang, J., Sun, M., Wang, Y., Huang, W., & Xia, L. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.07.004 · Cited by 9
OMIP‐105: A 30‐color full‐spectrum flow cytometry panel to characterize the immune cell landscape in spleen and tumor within a syngeneic MC ‐38 murine colon carcinoma model
DeNiro, G., Que, K., Fujimoto, T., Koo, S. M., Schneider, B., Mukhopadhyay, A., Kim, J. G., Sawant, A., & Nguyen, T. A. (2024) · Cytometry Part A · doi:10.1002/cyto.a.24886 · Cited by 9
Innovative gene engineering and drug delivery systems for dendritic cells in cancer immunotherapy
Prakash, M., Cortez, C. D., Jayaraman, A., Hsu, S.-Y., Huang, Y., Yeh, C.-Y., & Lee, Y. L. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01191-1 · Cited by 9
Targeting T cell exhaustion in colorectal cancer: emerging roles of LAG-3, TIM-3, and TIGIT signaling in overcoming immunotherapy resistance
Zamani, P., Barootchi, E., Firouzabadi, A., Tonekaboni, M. S., Saleki, K., Yazdanpanah, N., & Rezaei, N. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-025-02638-6 · Cited by 9
Cross‐regulation by TLR4 and T cell Ig mucin‐3 determines severity of liver injury in a CCl4‐induced mouse model
Zhao, L., Liang, J., Rao, W., Cui, M., Ren, S., Zhang, L., Xu, D., Han, Q., Zang, Y., & Zhang, B. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12851 · Cited by 9
Dimerization of Transmembrane Proteins in Cancer Immunotherapy
Li, L., & Li, J. (2023) · Membranes · doi:10.3390/membranes13040393 · Cited by 9
Artificial Dendritic Cells: A New Era of Promising Antitumor Immunotherapy
Mateus, D., Sebastião, A. I., Frasco, M. F., Carrascal, M. A., Falcão, A. C., Gomes, C. M. F., Neves, B. M., Sales, M. G. F., & Cruz, M. T. (2023) · Small · doi:10.1002/smll.202303940 · Cited by 9
The role of HMGB1 in digestive cancer
Chen, X., Liu, Q., Wu, E., Ma, Z., Tuo, B., Terai, S., Li, T., & Liu, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115575 · Cited by 9
Establishment of novel anti-TIM-3 antibodies interfering with its binding to ligands
Yan, Z., Ma, T., Wang, X., Yi, L., Wei, P., Zhang, H., & Wang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28126 · Cited by 9
G protein‐coupled receptor‐mediated signaling of immunomodulation in tumor progression
Qiu, G., Yu, B., & Ma, M. (2024) · The FASEB Journal · doi:10.1096/fj.202400458r · Cited by 9
Novel insights into immune cells modulation of tumor resistance
Zhou, Y., Na, C., & Li, Z. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104457 · Cited by 9

Authors: Chiba, S., Baghdadi, M., Akiba, H., Yoshiyama, H., Kinoshita, I., Dosaka-Akita, H., Fujioka, Y., Ohba, Y., Gorman, J. V., Colgan, J. D., Hirashima, M., Uede, T., Takaoka, A., Yagita, H., & Jinushi, M.
Affiliations: Hokkaido University (JP)
Juntendo University (JP)
University of Iowa (US)
Kagawa University (JP)
Corresponding author: Jinushi, Masahisa
ORCID: Baghdadi, Muhammad
Akiba, Hisaya
Yoshiyama, Hironori
Kinoshita, Ichiro
Fujioka, Yoichiro
Ohba, Yusuke
Colgan, John D
Hirashima, Mitsuomi
Takaoka, Akinori
Venue: Nature Immunology
Publisher: Springer Science and Business Media LLC
Published: 2012-07-29
Volume: 13
Issue: 9
Pages: 832-842
ISSN: 1529-2908 (ISSN-L)
1529-2916
DOI: 10.1038/ni.2376
PMC: PMC3622453
OpenAlex: W2112400160
Cited by: 838
References: 50
Citations by year: 2026: 40 · 2025: 53 · 2024: 81 · 2023: 82 · 2022: 83 · 2021: 80 · 2020: 65 · 2019: 63 · 2018: 56 · 2017: 48 · 2016: 53 · 2015: 41 · 2014: 39 · 2013: 39 · 2012: 15
FWCI: 18.74
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: www.springer.com/tdm (tdm)
Locations: Nature Immunology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Institutional Repositories DataBase (IRDB) (submittedVersion)
Hokkaido University Collection of Scholarly and Academic Papers (Hokkaido University) (submittedVersion)
Funders: Japan Society for the Promotion of Science (23590534, 23591132, 23501283, 22590360, 23390090, 22591098, 22240089, 23659196, 21390113)
National Institute of Allergy and Infectious Diseases (R01AI093737, R01AI067489)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: TIM-3, HMGB1, tumor-associated dendritic cells, nucleic acid sensing, innate immunity, tumor microenvironment, Toll-like receptors, galectin-9, DNA vaccine, chemotherapy, antitumor immunity, alarmins
MeSH terms: Hepatitis A Virus Cellular Receptor 2, Animals, Dendritic Cells, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Humans, Immunity, Innate, Immunologic Surveillance, Mice, Inbred C57BL, Microscopy, Fluorescence, Neoplasms, Nucleic Acids, Receptors, Virus, Immunoblotting, Microscopy, Confocal, Reverse Transcriptase Polymerase Chain Reaction, HMGB1 Protein, Receptors, Pattern Recognition, Mice, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks